Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.81 USD
-0.11 (-5.73%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $1.80 -0.01 (-0.55%) 7:14 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
Esperion Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ESPR 1.81 -0.11(-5.73%)
Will ESPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Other News for ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ESPR Stock News
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ...
Esperion Therapeutics (ESPR) Sees Revenue Surge, Eyes Profitability by 2026
Q2 2025 Esperion Therapeutics Inc Earnings Call Transcript
Esperion rises after revenue beat, Q1 profitability expectation